

Washed blood components in adult acute leukemia

Submission date 02/12/2004	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 06/12/2004	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 14/08/2009	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Neil Blumberg

Contact details
601 Elmwood Avenue
Box 608
Rochester
United States of America
14642
+1 585 275 9656
neil_blumberg@urmc.rochester.edu

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised active controlled parallel group trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Acute Leukemia

Interventions

The control intervention was leukocyte reduced red cell and platelet transfusions, the standard practice in most hospitals.

The experimental intervention was leukocyte reduced red cell and platelet transfusions that had also been plasma reduced by washing.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Added 14/08/09:

1. Platelet transfusion refractoriness
2. Infectious and bleeding complications
3. Overall survival.

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1991

Completion date

31/12/1994

Eligibility

Key inclusion criteria

Adult patients with acute leukemia undergoing full dose remission induction chemotherapy.

Participant type(s)

Patient

Age group

Adult

Sex

Not Specified

Target number of participants

43

Key exclusion criteria

Does not match inclusion criteria

Date of first enrolment

01/01/1991

Date of final enrolment

31/12/1994

Locations

Countries of recruitment

United States of America

Study participating centre

601 Elmwood Avenue
Rochester
United States of America
14642

Sponsor information

Organisation

University of Rochester (USA)

Sponsor details

601 Elmwood Avenue
Rochester
United States of America
14642
neil_blumberg@urmc.rochester.edu

Sponsor type

University/education

ROR

<https://ror.org/022kthw22>

Funder(s)

Funder type

University/education

Funder Name

University of Rochester (USA)

Funder Name

CaridianBCT Inc. (formerly Gambro BCT Inc.) (USA)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	10/12/2004		Yes	No